The model is part of an analgesic (read: pain relief) program the company launched in 2018 to develop peptide-based therapeutics for moderate-to-severe pain and inflammation. Peptides are made up of short chains of amino acids, which themselves are the building blocks of proteins.
In rodents, the peptides demonstrated analgesic activity at relatively low doses with effects lasting for up to two hours, the company said. Additionally, the peptides did not affect inflammation in the pain model, suggesting their effects were associated with an opioid-like analgesic effect.
PreveCeutical is also currently conducting pharmacokinetic studies, which analyze the movement of drugs within the body, on certain lead peptides.
“We are looking forward to the results of the PK studies,” CEO Stephen Van Deventer said in a statement. “This brings us closer to finding non-addictive pain therapies. We will be investigating patenting the lead peptides once the study is completed. The company is looking forward to adding this to our pipeline of intellectual property."
PreveCeutical focuses on developing options for preventative and curative therapies utilizing organic and nature identical products. The company’s current R&D programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel